Pennymac, UWM, loanDepot lag in RMBS issuance as Rocket grabs share

BTIG reports Pennymac, UWM, and loanDepot's Q3 agency MBS issuance lagged estimates, while Rocket and Onity exceeded expectations. Industry-wide MBS issuance fell 4% in September, with non-QM issuance down 18% QoQ but up 6% YoY. BTIG revised 2023 and 2024 origination forecasts downward, citing elevated mortgage rates and seasonal slowdowns.

Original reporting
Published Oct 2, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 11:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pennymac, UWM, loanDepot lag in RMBS issuance as Rocket grabs share — source image
Decision brief

The 30-second read

$PMTBearishLow
01

Why it matters

The report provides fresh data on issuance performance, a key leading indicator for mortgage lenders.

02

Market read

Issuance shortfalls signal weaker loan pipelines, affecting earnings outlooks for major U.S. mortgage lenders.

03

What to watch

Potential boost from home‑equity lending at loanDepot and upcoming Mr. Cooper integration at Rocket.

Relevance 4/10Novelty 3/10Timing: today

Background

BTIG's latest Mortgage Originators report compares third‑quarter RMBS issuance against internal and consensus forecasts, highlighting sector‑wide slowdown.

Company-level read

Ticker impact

$PMTBearishHigh confidence
Context

Pennymac's RMBS issuance fell far below BTIG estimates, losing about 500 bps of market share.

Expected impact

potential decline as investors price in lower loan volume and market‑share loss

Evidence & confidence

BTIG report highlights a material miss versus expectations, which typically drags the stock.

$RCKTBullishHigh confidence
Context

Rocket Companies posted a 10.5% market share of retail purchase MBS issuance in September, up 110 bps from August.

Expected impact

upward pressure as market rewards higher share gains

Evidence & confidence

Rocket's strong issuance performance contrasts with peers and may boost valuation multiples.

Market effects

Mortgage‑backed securities issuance weakness may weigh on the broader mortgage‑lender sector.

U.S. mortgage originators could see tighter spreads and lower loan volumes.

Limited to U.S. housing finance; minimal direct global spillover.

Counterpoint

If interest‑rate volatility stabilizes, the issuance miss may be temporary and stocks could rebound.

Key entities

  • BTIG

    Provides mortgage‑originator coverage and issuance forecasts.

Related articles

$RCKTMed

Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral, citing encouraging clinical updates on its gene therapy candidate RP-A501. The company remains unprofitable with no revenue, but its market cap of $284M reflects growth expectations. RCKT's GF Score is 35/100, showing mixed fundamentals. Insiders have sold shares, while some institutional investors hold positions.

$RCKTHigh

Why is Rocket Pharmaceuticals stock up 3% today?

Rocket Pharmaceuticals (RCKT) rose 2.8% after Goldman Sachs upgraded it to Neutral with a $4.00 price target, citing positive clinical data for RP-A501. Other analysts maintained bullish ratings, while some lowered targets due to long timelines. The company secured a $150M credit facility. The move was company-specific, as broader markets were down.

$RCKTMedAI 8/10

Rocket Pharmaceuticals bags $150 million as it pushes pivotal Danon disease study

Rocket Pharmaceuticals secured up to $150 million in financing from Hercules Capital, including an initial $35 million. The funds will support a pivotal Phase 2 study for its gene therapy candidate RP-A501 for Danon disease and broader cardiovascular pipeline development. The company reported $283.7 million in cash as of June 30, 2026, and expects the financing to extend its cash runway.